New therapeutic directions for advanced pancreatic cancer: cell cycle inhibitors, stromal modifiers and conjugated therapies
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
New therapeutic directions for advanced pancreatic cancer: cell cycle inhibitors, stromal modifiers and conjugated therapies
Authors
Keywords
-
Journal
EXPERT OPINION ON EMERGING DRUGS
Volume 22, Issue 3, Pages 223-233
Publisher
Informa UK Limited
Online
2017-08-08
DOI
10.1080/14728214.2017.1362388
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
- (2016) Andrea Wang-Gillam et al. LANCET
- A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial†
- (2015) C. S. Fuchs et al. ANNALS OF ONCOLOGY
- Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells
- (2015) Shin Kan et al. BMC CANCER
- Pancreatic Cancer Metastasis: Are we being Pre-EMTed?
- (2015) Srustidhar Das et al. CURRENT PHARMACEUTICAL DESIGN
- A phase I trial of mFOLFOX6 combined with the oral PI3K inhibitor BKM120 in patients with advanced refractory solid tumors
- (2015) Autumn J. McRee et al. INVESTIGATIONAL NEW DRUGS
- Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer
- (2015) Mitesh J. Borad et al. JOURNAL OF CLINICAL ONCOLOGY
- Hyaluronan stimulates pancreatic cancer cell motility
- (2015) Xiao-Bo Cheng et al. Oncotarget
- A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas
- (2014) Jeffrey R. Infante et al. EUROPEAN JOURNAL OF CANCER
- Advanced stage pancreatic cancer: novel therapeutic options
- (2014) Muhammad Wasif Saif Expert Review of Clinical Pharmacology
- A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer
- (2013) A H Ko et al. BRITISH JOURNAL OF CANCER
- Targeting the PDGF signaling pathway in tumor treatment
- (2013) Carl-Henrik Heldin Cell Communication and Signaling
- Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: A phase II randomised trial
- (2013) Michele Reni et al. EUROPEAN JOURNAL OF CANCER
- Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer
- (2013) Philippe Rougier et al. EUROPEAN JOURNAL OF CANCER
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer
- (2012) H. L. Kindler et al. ANNALS OF ONCOLOGY
- PDGFRβ expression in tumor stroma of pancreatic adenocarcinoma as a reliable prognostic marker
- (2012) Sayaka Yuzawa et al. MEDICAL ONCOLOGY
- Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial
- (2011) J. M. Lohr et al. ANNALS OF ONCOLOGY
- Deconstructing the mechanisms and consequences of TGF-β-induced EMT during cancer progression
- (2011) Michael K. Wendt et al. CELL AND TISSUE RESEARCH
- Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors
- (2011) P. M. LoRusso et al. CLINICAL CANCER RESEARCH
- Trastuzumab Emtansine: A Unique Antibody-Drug Conjugate in Development for Human Epidermal Growth Factor Receptor 2-Positive Cancer
- (2011) P. M. LoRusso et al. CLINICAL CANCER RESEARCH
- Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: A phase III-study from the German CONKO-study group
- (2011) Uwe Pelzer et al. EUROPEAN JOURNAL OF CANCER
- Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis
- (2011) J. Y. Guo et al. GENES & DEVELOPMENT
- Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial
- (2011) Daniel D. Von Hoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study
- (2011) Hedy L Kindler et al. LANCET ONCOLOGY
- Metastatic pancreatic cancer—is FOLFIRINOX the new standard?
- (2011) M. Wasif Saif et al. Nature Reviews Clinical Oncology
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Stromal biology and therapy in pancreatic cancer
- (2010) A. Neesse et al. GUT
- Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
- (2010) Hedy Lee Kindler et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group–Directed Intergroup Trial S0205
- (2010) Philip A. Philip et al. JOURNAL OF CLINICAL ONCOLOGY
- A Cancer and Leukemia Group B Phase II Study of Sunitinib Malate in Patients with Previously Treated Metastatic Pancreatic Adenocarcinoma (CALGB 80603)
- (2010) E. M. O'Reilly et al. ONCOLOGIST
- Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer
- (2009) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer
- (2009) K. P. Olive et al. SCIENCE
- Sonic Hedgehog Promotes Desmoplasia in Pancreatic Cancer
- (2008) J. M. Bailey et al. CLINICAL CANCER RESEARCH
- Fluorouracil vs Gemcitabine Chemotherapy Before and After Fluorouracil-Based Chemoradiation Following Resection of Pancreatic Adenocarcinoma
- (2008) William F. Regine et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Clinical Benefit and Quality of Life in Patients With Advanced Pancreatic Cancer Receiving Gemcitabine Plus Capecitabine Versus Gemcitabine Alone: A Randomized Multicenter Phase III Clinical Trial—SAKK 44/00–CECOG/PAN.1.3.001
- (2008) Jürg Bernhard et al. JOURNAL OF CLINICAL ONCOLOGY
- Oral mTOR Inhibitor Everolimus in Patients With Gemcitabine-Refractory Metastatic Pancreatic Cancer
- (2008) Brian M. Wolpin et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation